Merck & Co Agrees to $300m Research Contract with Lycera
Merck & Co and Lycera have signed a preclinical research deal that could be worth up to $300m if certain milestones are met.
Archives for February 18, 2013
Quintiles Confirms 'Go Public' Speculation with IPO and Predicts Rosy Future for CROs
Quintiles painted a rosy picture of the CRO sector in its much anticipated IPO, predicting that biopharma R&D spending will increase and demand for outsourced research will grow.
AMRI to Focus on Large Scale Manufacturing
AMRI has predicted continuing revenue growth in its contract manufacturing with its API pipeline and once-troubled Burlington site leading the way.
Charles River Sees Flat Quarter, Expectations for 2013 Still High
CRL (Charles River Laboratories) saw a number of setbacks in the last quarter of 2012 but still expects growth in 2013.
update
Aesica and EmulTech Claim Micro-Encapsulation can Revive Formulation Projects
Aesica and EmulTech claim a new sterile formulation technology could help drugmakers resurrect abandoned projects and extend the lifespan of marketed medicines.